Results 1 to 10 of about 181,208 (343)
Streptozotocin‐Induced Diabetic Models in Mice and Rats
Current Protocols in Pharmacology, 2015 Streptozotocin (STZ) is an antibiotic that produces pancreatic islet β‐cell destruction and is widely used experimentally to produce a model of type 1 diabetes mellitus (T1DM).
B. Furman
exaly +2 more sources
Molecular Neurobiology, 2015 Streptozotocin (STZ), a glucosamine-nitrosourea compound derived from soil bacteria and originally developed as an anticancer agent, in 1963 has been found to induce diabetes in experimental animals.
Paweł Grieb
exaly +2 more sources
Modeling type 2 diabetes in rats using high fat diet and streptozotocin
Journal of Diabetes Investigation, 2014 The pathology of type 2 diabetes is complex, with multiple stages culminating in a functional β‐cell mass that is insufficient to meet the body's needs.
Søs Skovsø
exaly +2 more sources
Antidiabetic Activity of Zinc Oxide and Silver Nanoparticles on Streptozotocin-Induced Diabetic Rats
International Journal of Molecular Sciences, 2014 The use of nanoparticles in medicine is an attractive proposition. In the present study, zinc oxide and silver nanoparticles were evaluated for their antidiabetic activity. Fifty male albino rats with weight 120 ± 20 and age 6 months were used.
Ali Alkaladi, Aaser M Abdelazim
exaly +2 more sources
Streptozotocin‐Induced Diabetic Models in Mice and Rats
Current Protocols, 2021 Streptozotocin (STZ) is an antibiotic that causes pancreatic islet β‐cell destruction and is widely used experimentally to produce a model of type 1 diabetes mellitus (T1DM).
B. Furman
semanticscholar +1 more source
Effect of tyrosine protein kinase blockade on the state of retinal microglia in diabetic retinopathy
Mìžnarodnij Endokrinologìčnij Žurnal, 2023 Background. Impaired homeostasis of the retinal tissue in diabetes primarily involves microglia, which triggers a cascade of inflammatory reactions, one of the main mechanisms of diabetic retinopathy (DR).
V.V. Vodianyk +2 more
doaj +1 more source
Zaporožskij Medicinskij Žurnal, 2023 The development of pharmacological methods to control oxidant stress manifestations in diabetes can be achieved using organic complex germanium compounds.
V. Y. Kresiun, N. Al-Nadawi Javad
doaj +1 more source
Neuroendocrinology, 2022 In May 1982, the US Food and Drug Administration (FDA) approved the use of streptozotocin to treat pancreatic neuroendocrine tumors (panNETs). Thus, this year marks 40 years since that landmark date.
J. Capdevila +9 more
semanticscholar +1 more source
HYPOGLYCEMIC EFFECT OF SITAGLIPTIN AND AMINOGUANIDINE COMBINATION IN EXPERIMENTAL DIABETES MELLITUS
Фармация и фармакология (Пятигорск), 2023 The aim of the work was to determine the antidiabetic effect of a sitagliptin and aminoguanidine combination in rats with experimental diabetes mellitus.Materials and methods.
D. V. Kurkin +9 more
doaj +1 more source
Evidence-Based Complementary and Alternative Medicine, 2022 Oxidative stress and inflammation have been shown to interact and have the role of importance in causing diabetic nephropathy complications. Fucoidan has a strong antioxidant and anti-inflammation effect, so the aim of this research was to evaluate the ...
G. Wardani +3 more
semanticscholar +1 more source